Currently, four monoclonal antibodies (mAb) targeting the extracellular domain of EGFR are approved for clinical use against various cancers of epithelial origin (e.g., colorectal cancer (CRC) and head and neck cancer) [20]. Here, EGFR is linked to colorectal carcinoma.